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Background: Facioscapulohumeral muscular dystrophy type 1(FSHD1) is an autosomal dominant disorder
associated with the contraction of D4Z4 less than 11 repeat units (RUs) on chromosome 4q35. Penetrance in the
range of the largest alleles is poorly known. Our objective was to study the penetrance of FSHD1 in patients
carrying alleles ranging between 6 to10 RUs and to evaluate the influence of sex, age, and several environmental
factors on clinical expression of the disease.
Methods: A cross-sectional multicenter study was conducted in six French and one Swiss neuromuscular centers.
65 FSHD1 affected patients carrying a 4qA allele of 6–10 RUs were identified as index cases (IC) and their 119 at-risk
relatives were included. The age of onset was recorded for IC only. Medical history, neurological examination and
manual muscle testing were performed for each subject. Genetic testing determined the allele size (number of RUs)
and the 4qA/4qB allelic variant. The clinical status of relatives was established blindly to their genetic testing results.
The main outcome was the penetrance defined as the ratio between the number of clinically affected carriers and
the total number of carriers.
Results: Among the relatives, 59 carried the D4Z4 contraction. At the clinical level, 34 relatives carriers were
clinically affected and 25 unaffected. Therefore, the calculated penetrance was 57% in the range of 6–10 RUs.
Penetrance was estimated at 62% in the range of 6–8 RUs, and at 47% in the range of 9–10 RUs. Moreover,
penetrance was lower in women than men. There was no effect of drugs, anesthesia, surgery or traumatisms on
the penetrance.
Conclusions: Penetrance of FSHD1 is low for largest alleles in the range of 9–10 RUs, and lower in women than
men. This is of crucial importance for genetic counseling and clinical management of patients and families.
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Facioscapulohumeral muscular dystrophy (FSHD) is an
autosomal dominant disorder with variable severity and
inter- and intra-familial heterogeneity [1,2]. FSHD is
characterized by a highly selective and asymmetrical
pattern of muscle involvement. For two decades, the
molecular diagnosis of FSHD type 1 (FSHD1) has been
supported by the evidence of a heterozygous contraction
of the D4Z4 repeat array from 1 to 10 repeat units (RUs)
on 4q35 [3].
D4Z4 contraction is considered to be pathogenic if it oc-
curs on a specific chromosomal background, i.e., (i) the
presence of the 4A (159/161/168) haplotype and (ii) a
single nucleotide polymorphism that creates a polyadeny-
lation site (PAS) for the distal DUX4 transcript [4-6]. The
unique association of FSHD1 with a specific haplotype re-
mains controversial as some FSHD1 patients carry a
D4Z4 contraction without the common 4A161PAS haplo-
type [7]. The pathological cut-off is conventionally deter-
mined at 10 RUs. Most FSHD1 patients carry 1 to 8 RUs
on one allele. Large studies provided data on expressivity
and penetrance in this range [8,9]. However, few studies
reported the phenotypic spectrum associated with the
upper pathological alleles (9–10 RUs). It was suggested
that these patients present with a later and milder pheno-
type and a lower penetrance [10-14]. A better knowledge
of penetrance in this range is necessary for improving gen-
etic counseling, particularly in the context of predictive
testing and prenatal diagnosis in FSHD families.
In our study, we aimed to estimate the penetrance in a
large group of FSHD1 patients with alleles of 6–10 RUs.
In addition, we evaluated the influence of sex, age, and
several environmental factors on clinical expression of
the disease.
Methods
A cross-sectional multicenter study was conducted in six
French and one Swiss neuromuscular centers. Among
the FSHD cases followed in the reference centers from
2007 to 2009, patients carrying a contracted D4Z4 array
with an estimated size of 6 RUs (27 kb) to 10 RUs
(40 kb) and fulfilling the diagnostic criteria defined by the
European Expert Group on FSHD [15] were selected to
constitute the index case (IC) group. The second group
included volunteer at-risk relatives with various degrees of
kinship. For ethical considerations, we did not include
patients less than 18 years of age or pregnant women.
At each center, patients and relatives were examined by
a pluridisciplinary team that included a neurologist with
neuromuscular disorder expertise, a geneticist and a
physiotherapist. All clinical data were collected and blood
was sampled for genetic analysis during a single visit.
All subjects enrolled in the study gave informed con-
sent to participate. This study received the approval ofthe local ethic committee (Comité de Protection des
Personnes Sud Mediterranée I).
Clinical and functional evaluation
For each IC or relative, we recorded the following: med-
ical history, self-evaluation of physical activity, pedigree,
clinical examination, functional assessment, and manual
muscular test results. ICs and relatives were asked for
information pertaining to physical activity (self eva-
luation of physical activity), number of trauma requiring
an immobilization of one week or more,, number of ex-
posures to and types of anesthesia received, exposure to
tobacco (number of pack-years of cigarettes), alcohol in-
take (average number of alcohol units per day and per
week), and the use of any drugs. The first symptom ex-
perienced and the age of onset were recorded for ICs
only. We did not record the age of onset in relatives be-
cause some of them had never been examined before
and did not want their clinical status to be revealed.
Therefore, we established the age at examination as the
age of onset for clinically affected relatives. Neurologists
examined the presence or absence of scapular winging,
facial, limbs and thoraco-abdominal muscle weakness,
selective involvement and asymmetry of muscle weak-
ness. At the end of clinical examination, the neurologist
blinded to the genetic results determined if the relative
was clinically affected or not. The guidelines were to
consider that a relative was clinically affected if there
was facial and/or scapular fixator weakness; and there
was absence of atypical signs suggesting an alternative
diagnosis (including extraocular, masticatory, pharyngeal,
or lingual muscle weakness and cardiomyopathy) [10,15].
Genetic testing
Informed consent was obtained for every enrolled sub-
ject. In the relatives group, each participant was asked if
he wanted to be informed about his own genetic results.
Subjects who wished to be informed were given their
genetic result by the geneticist during a genetic coun-
seling session at the end of the study. The genetic result
was validated by a second analysis on a new DNA sample.
Each patient’s blood sample was coded and anonymized.
All genetic analyses were performed at the Laboratory
of Molecular Genetics in the Department of Medical
Genetics in Marseille. DNA was prepared from isolated
lymphocytes according to standard procedures. Restric-
tion endonuclease digestion was performed and digested
DNA was separated by pulsed-field gel electrophoresis
(PFGE) in a 1% agarose gel. Allele sizes were estimated by
Southern blot hybridization with a radiolabeled p13E-11
probe using 7 μg of EcoRI and EcoRI/BlnI digested gen-
omic DNA. In our laboratory practice and according to
interlaboratory quality assessment, we consider that the
pathological cut-off at 10 RUs corresponds to an EcoRI
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sponds to fragments from 27-40 kb. The molecular results
in our diagnostic laboratory are provided in RUs. The
4qA/4qB allelic variants were identified using 7 μg of Hin-
dIII digested DNA, PFGE electrophoresis, and Southern
blot hybridization with radiolabeled probes for qA/qB
according to standard procedures. The IC group was
analyzed with EcoRI/p13E-11, EcoRI/BlnI/p13E-11, and
HindIII/qAqB while the relatives group was analyzed by
comparing their EcoRI/BlnI/p13E-11 pattern with that of
the IC in each family. We considered as “carriers” the rela-
tives harboring the contracted allele previously identified
in the IC. We did not perform the analysis of the SSLP-
PAS sequence, as the recent literature indicates that only
50% of FSHD1 patients carry the 4A161PAS permissive
haplotype associated with the D4Z4 contraction. Thus, we
did not consider this parameter as mandatory for molecu-
lar diagnosis [16].
Statistical analyses
To examine group comparability, we compared the age
and sex of ICs, clinically affected carriers, clinically un-
affected carriers, and non carriers. To study the in-
fluence of age, sex, and environmental factors on the
risk of being clinically affected, we compared clinically
affected versus clinically unaffected carriers.
For all mean comparisons, the Student’s t-test or ana-
lysis of variance were used. Frequencies were compared
using a chi-square test. When necessary, nonparametric
tests (Mann–Whitney or Kruskal–Wallis tests) or Fisher
exact tests were used. Differences were considered sig-
nificant for all analyses when the P values were lower
than 0.05.
The risk of developing symptoms of the disease con-
sidering age, sex and number of RUs was estimated for
clinically affected patients (IC and clinically affected
carriers) versus clinically unaffected carriers using the
multivariate logistic regression model. Odds ratios (ORs)
and 95% confidence intervals (CIs) were calculated for
age (continuous variable), sex and number of RUs classi-
fied into two categories (6–8 RUs, 9–10 RUs).
To estimate the penetrance, the primary criterion was
the clinical status established by neurologists blinded
with regard to genetic status. Penetrance was defined as
the ratio between the number of carriers considered as
clinically affected and the total number of carriers. In
order not to underestimate the penetrance by taking in
account the at-risk relatives only, we estimated the pene-
trance as a range between two figures including or ex-
cluding the ICs.
The Kaplan–Meier survival analysis was used for ICs
and clinically unaffected carriers to estimate the age-
specific cumulative first symptom incidence with the
corresponding 95% CIs. For each IC, the time from birthto the earliest declarative age at onset of symptoms was
collected. For clinically unaffected carriers, we con-
sidered the age at the time of the clinical evaluation.
Results
184 subjects were included in the study, 65 ICs and 119
relatives (Figure 1). Forty-four families encompassed less
than 4 individuals and 21 families encompassed between
4 and 9 individuals. All ICs harbored a 4qA contracted
allele. Among the 119 relatives, 59 were carriers of the
D4Z4 contraction identified in the IC, and 60 were non
carriers. Among the 59 relatives, 34 were clinically af-
fected carriers and 25 were unaffected carriers.
Overall, 124 were carriers of the contraction, of which
99 individuals were clinically affected (65 ICs and 34
affected relatives).
Demographic characteristics of the subjects
Descriptive statistics of age and sex are described in
Table 1. Of the 99 clinically affected individuals (ICs and
affected carriers), there were 62 men and 37 women. In
the remaining unaffected carrier patients group, there
were significantly more women (18 of 25, p = 0.002).
The age of the patients at the time of clinical evaluation
did not significantly differ between ICs, affected carriers,
unaffected carriers, and non carriers. Table 2 summa-
rizes the phenotype observed in the index cases and the
affected carriers.
In the IC group (n = 65), the mean age at onset was
30.0 years (±16.5). Thirty-four patients (52.3%) had devel-
oped symptoms before 30 years of age. The mean age at
diagnosis was 44.2 years (±15.9). The mean disease dur-
ation at inclusion was 7.2 years (±6.9). The mean diagnosis
delay was 14.2 years (ranging 1–49 years). The type of first
symptoms experienced by patients was scapulo-humeral
weakness in 40 patients (61.5%), facial weakness in 3 pa-
tients (4.6%), lower limb weakness in 18 patients (27.7%),
muscle pain in 2 patients (3.0%), clumsiness in one patient
(1.5%) and not informed in one patient. When comparing
the, ICs carrying 6–8 RUs (n = 49) and those carrying
9–10 RUs (n = 16), we found a higher proportion of pa-
tients developing symptoms before 30 years in the 6–8
RUs subgroup (59.2%) than in the 9–10 RUs subgroup
(31.3%), although it did not reach statistical significance
(p = 0.052). Of 7 patients in the IC group (2 men and 5
women) who were wheelchair-bound (mean age 60.9
years), six of them belonged to the 6–8 RUs subgroup.
The relatives were divided into the two subgroups by
number of RUs: 6–8 RUs (n = 40) and 9–10 RUs (n = 19).
Study of penetrance
Overall, among the 124 carriers, 99 subjects were clini-
cally affected (65 ICs and 34 relatives), which leads to es-
timate the penetrance of the disease in the whole group
Included Subjects = 194
Index cases = 67 Relatives = 127
Clinical examination performed blindly
versus to molecular analysis
65 index cases
(IC)
34 Relatives
Clinically affected carriers
of a D4Z4 contraction
25 Relatives
Clinically unaffected 
carriers
of a D4Z4 contraction
60 Relatives 
Clinically unaffected
non carriers
2 index cases excluded: 
genetic results non 
reliable
99 cases
Clinically affected
subjects
25 cases
Clinically 
unaffected 
subjects
8 relatives excluded:
- 4 genetics results non reliable
- 4 incomplete examination
59 Relatives used for penetrance estimation
Figure 1 Repartition of subjects included in the study.
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are included). In the 6–8 RUs subgroup, penetrance var-
ied from 62 to 83% whereas in the 9–10 RUs subgroup,
it ranged from 47% to 71%. We found a higher propor-
tion of clinically unaffected versus clinically affected car-
riers in the 9–10 RUs group than in the 6–8 RUs group,
although it did not reach the statistical significance.
An age-related cumulative frequency of penetrance
was estimated using the Kaplan–Meier method on the
data obtained from 65 ICs and 25 unaffected carriersTable 1 Descriptive statistics of age and sex
ICs n (%) Affected carriers
65 34
Gender
Male 44 (68%)a,b 18 (53%)
Female 21 (32%) 16 (47%)
Age, years (mean ± standard deviation) 51.2 ± 14.9 50.5 ± 17.4
Overall age comparison: Kruskall–Wallis test p = 0.482. Overall gender comparison: c
unaffected carriers p = 0.0007 and bICs versus non carriers p = 0.001.(Figure 2 and Table 3). In the 6–8 RUs subgroup, the
risk of developing motor impairment was 35% by age 20,
60% by age 40 and 81% by age 60, whereas in the 9–10
RUs subgroup, the risk was 19% by age 20, 44% by age
40, and 71% by age 60.
Influence of age, sex, environmental factors and degree
of kinship on penetrance
In order to evaluate the influence of age, sex, and environ-
mental factors on penetrance, we compared the affectedn (%) Unaffected carriers n (%) Non carriers n (%) P value
25 60
0.002
7 (28%)a 24 (40,%)b
18 (72%) 36 (60%)
47.6 ± 19.5 46.9 ± 17.4 0.482
hi square test p = 0.002. Significant pairwise comparisons: aICs versus
Table 2 Phenotype in index cases and affected carriers at
the time of examination
ICs Affected carriers
n (%) n (%)
Facial weakness 49 (75%) 20 (59%)
Scapular weakness 65 (100%) 32 (94%)
Pectoral weakness 55 (85%) 20 (59%)
Abdominal weakness 51 (78.5%) 20 (59%)
Asymmetry 49 (75%) 23 (68%)
Steppage 31 (48%) 2 (6%)
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the age criterion. Seventy two percent of the unaffected
carriers (18/25) were women, although it did not reach
statistical significance (p = 0.055). There was no difference
of smoking habits or intake of alcohol between the two
groups. Regarding medical history (high blood pressure,
cardiovascular diseases, diabetes mellitus, cancer, thyroid
disorders, trauma, and anesthesia), level of physical activity,
and exposure to medication (analgesics, anti-inflammatory,
cholesterol-lowering drugs, or anti-depressants), there was
no difference either. We did not find any effect of the
degree of kinship.
The risk of developing FSHD between clinically affected
patients (ICs and affected carriers, n = 99) and clinically
unaffected carriers (n = 25) was evaluated by logistic
regression analysis. There was no significant effect of age
on the risk of developing motor impairment (OR = 1.02,
CI = 0.99–1.05). The risk of developing symptoms of
FSHD was 4.6-fold higher (p = 0.0041; OR = 4.6, CI = 1.6–
12.8) for men than for women, suggesting a significantFigure 2 Age-related cumulative risk of being clinically affected accor
unaffected carriers using the Kaplan-Meier analysis. Blue line refers to 6–8 R
Log-Rank test P = 0.0584.effect of sex in the disease. Regarding the influence of the
number of RUs on penetrance, the risk of developing
symptoms of FSHD was not significantly increased in
patients with 6–8 RUs versus in patients with 9–10 RUs
(p = 0.72; OR = 2.01, CI = 0.74–5.50).
Discussion
We have conducted a cross-sectional multicenter study
of the penetrance in FSHD1 patients carrying contracted
alleles of 6–10 RUs. In this range, the penetrance was es-
timated to be 57% (if ICs are excluded) or 79% (if ICs
are included). The penetrance was lower in patients with
9–10 RUs (47% if ICs are excluded or 71% if ICs are in-
cluded) than in those with 6–8 RUs (62% if ICs are ex-
cluded or 83% if ICs are included).
In the premolecular era, the penetrance of FSHD1 was
considered to be age-related and almost complete at age
20 [17]. When including D4Z4 analyses, the penetrance
was shown to be incomplete but higher than 80%
[13,14,18,19]. More recently, the penetrance was shown
to be lower than expected. In a retrospective study of 85
Japanese families, including sporadic and familial cases,
Goto et al. [20] observed a penetrance of 59%. Of late, a
Greek survey of 133 patients estimated that the penetrance
ranged from 50 (ICs excluded) to 77% (ICs included) in
FSHD1 patients carrying a contracted allele ≤38 kb [9]. In
addition, in a large Italian cohort, Ricci et al. estimated
the penetrance in patients with alleles of 1–8 RUs [8].
The estimated risk of developing motor impairment by
age 60 for relatives carrying 1–3 RUs and 4–8 RUs was
96.2% and 71.5%, respectively. These results suggest an
inverse relationship between penetrance and size of the
contracted allele.ding to the number of RUs. Estimates obtained on 65 IC and 25
Us; Red line refers to 9–10 RUs. Carriers 6–8 RUs versus 9–10 RUs,
Table 3 Estimates of the age-specific cumulative risk
using Kaplan–Meier analysis
Age 6–8 RUs 9–10 RUs
(years) Risk 95% CI Risk 95% CI
20 35.1 (25.0; 49.1) 19.2 (8.7; 42.3)
30 47.2 (36.1; 61.6) 27.3 (14.5; 51.4)
40 60.4 (48.9; 74.5) 44.0 (28.2; 68.7)
50 72.0 (61.1; 85.0) 63.3 (46.1; 86.9)
60 81.1 (70.2; 93.7) 70.6 (52.7; 94.5)
70 89.5 (78.9; 100)
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trance data are scarce to date. Clinical reports have
suggested that the penetrance in this range is low, but it
has never been calculated through large family studies
[10,11,21,22]. Our cohort is the largest one including
FSHD1 families with contracted alleles in the upper range
of pathological alleles (9–10 RUs). We showed that the
age-related cumulative risk of being clinically affected was
lower in patients with 9–10 RUs than in patients with 6–8
RUs (70% versus 81% at age 60), although the difference
was not statistically significant. To compare, in the Italian
survey, the risk of being clinically affected in patients with
7–8 RUs was lower than in patients with 4–6 RUs (63%
versus 71% at age 60) [8]. Our study suggests the same
inverse relationship between penetrance and size of the
contracted allele in the range 9–10 RUs, as observed for
alleles smaller than 8 RUs.
In our study, the mean age of onset (30 yo) was higher
than reported in previous studies, ie 16 years [23] and
23 years [24]. In our cohort, only 52% of ICs had deve-
loped symptoms before 30, contrasting with the 70% re-
ported elsewhere [25]. Several studies in FSHD1 have
shown a significant correlation between age at onset and
EcoRI fragment size [26]. All the previous studies in-
cluded patients with alleles <6 RUs while we excluded
them from our cohort. Accordingly, our data suggest
that the disease onset in patients with the largest alleles
is later than in those with the shortest alleles. In agree-
ment with previous studies, we found a significant effect
of sex on FSHD1 penetrance, with women being less
clinically affected than men [2,8,14,18,19]. Our data
confirm the influence of sex, even in alleles in the upper
range.
The concordance between the clinical status deter-
mined by the neurological examination and the results
of the genetic analysis was complete in this study, em-
phasizing the high predictive value of clinical expertise
in accurate FSHD diagnosis. Regarding the mode of on-
set of the disease, the first symptom was scapulohumeral
weakness in 61% of patients, as in previous studies [8,9].
The onset in the lower limbs was higher in our series(28%) than previously reported (11.7 to 16.7%) [8,9]. Fur-
thermore, only 10.7% of our ICs were wheelchair-bound
(mean age of 50 years; mean disease duration of 7 years)
while previous studies reported that approximately 20%
of FSHD1 patients become wheelchair-bound by the age
of 50 [9,27,28]. We hypothesize that in the range of the
upper alleles, the clinical course of the disease is less se-
vere in line with the fact that the most severe phenotypes
usually result from the shortest alleles (1–3 RUs) [29,30].
In addition, we searched for an environmental effect
that could influence the FSHD1 penetrance. We did not
find any effects of drugs, anesthesia, surgery or trauma-
tisms on the penetrance. Nevertheless, the number of
patients included in this study was too small for epi-
demiological studies. Further investigations in large co-
horts are needed to exclude the effect of environmental
factors on FSHD. Besides, previous studies suggested
that epigenetic mechanisms or modifier genes influence
the clinical expression of FSHD [31].
Recently, a novel gene called SMCHD1 has been iden-
tified as causative in FSHD without D4Z4 contraction
(FSHD2), and has also been proposed as a modifier in
FSHD1 [32,33]. In our study, penetrance could have
been influenced by epigenetic factors, which should be
further explored.
Conclusion
In conclusion, penetrance is low in patients with alleles
in the upper range and lower in women than men. In
this range, the age of onset is later and the course of the
disease is less severe. Knowledge of penetrance and ex-
pressivity of FSHD1 is of crucial importance for genetic
counseling and clinical management of patients and
families. Our findings indicate that great caution must
be taken concerning predictive and prognostic informa-
tion provided to FSHD1 carriers of the largest alleles.
Deeper investigations of genotype-phenotype correla-
tions are ongoing in our cohort in order to provide a
precise characterization of this patient subgroup.
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